Human ubiquitin ligase E3 for the modulation of NF-xB
Details for Australian Patent Application No. 2004240212 (hide)
International Classifications
Event Publications
27 January 2005 Complete Application Filed
10 February 2005 Application Open to Public Inspection
Published as AU-A-2004240212
10 February 2005 Corrigenda
Complete Applications Filed - Name Index Under the name Yissum Research Development Company of the Hebrew University of Jerusalem; Signal Pharmaceuticals, LLC., Application No. 2004240212, under INID (54) correct the title to read Human ubiquitin ligase E3 for the modulation of NF-kappaB.
24 February 2005 Corrigenda
Applications OPI - Name Index Under the name Signal Pharmaceuticals, LLC. and Yissum Research Development Company of the Hebrew University of Jerusalem, Application No. 2004240212, under INID (54) correct the title to read Human ubiquitin ligase E3 for the modulation of NF-kappaB.
6 December 2007 Application Accepted
Published as AU-A-2004240212
3 April 2008 Standard Patent Sealed
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser